CIK 0001829635 · <br>Emerging growth company
Transcode Therapeutics, Inc.
Sign in to watch- Ticker
- RNAZ
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811065054
- Phone
- 857-301-6857
- Business address
- 6 LIBERTY SQUARE, #2382, BOSTON, MA, 02109
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-09 | Fitzgerald Thomas A Chief Financial Officer | Grant or award · Stock Option (right to buy) | +185,000 | 185,000 | ||
| 2026-08-03 | DEFJ, LLC 10% owner | Conversion | +11,813,859 | 12,113,899 | ||
| 2026-08-03 | DEFJ, LLC 10% owner | Conversion | +2,020,582 | 14,134,481 | ||
| 2026-08-03 | DEFJ, LLC 10% owner | Conversion · Series A Non-Voting Convertible Preferred Stock | −1,181.39 | 0 | ||
| 2026-08-03 | DEFJ, LLC 10% owner | Conversion · Series B Non-Voting Convertible Preferred Stock | −202.06 | 0 | ||
| 2024-06-14 | Marquet Magda Director | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2024-06-14 | Manting Erik Director | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2024-06-14 | Fitzgerald Thomas A Interim CEO, CFO | Grant or award · Stock Option (right to buy) | +650,000 | 650,000 | ||
| 2024-06-14 | Calais Philippe Director | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2023-09-28 | Fitzgerald Thomas A Chief Financial Officer | Purchase | +49,350 | $0.51 | $25K | 56,318 |
| 2023-09-28 | Dudley Robert Michael Chief Executive Officer | Purchase | +98,000 | $0.51 | $50K | 180,262 |
| 2023-06-21 | Dudley Robert Michael Chief Executive Officer | Purchase | +12,000 | $2.65 | $32K | 82,262 |
| 2023-06-20 | Dudley Robert Michael Chief Executive Officer | Purchase | +6,607 | $2.55 | $17K | 70,262 |
| 2023-06-09 | Dudley Robert Michael Chief Executive Officer | Purchase | +19,000 | $2.76 | $52K | 61,155 |
| 2023-06-09 | Dudley Robert Michael Chief Executive Officer | Purchase | +19,000 | $2.76 | $52K | 912,114 |
| 2023-05-19 | Manting Erik Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2023-05-19 | Marquet Magda Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2023-05-19 | Fitzgerald Thomas A Chief Financial Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2023-05-19 | Dudley Robert Michael Chief Executive Officer | Grant or award · Stock Option (right to buy) | +735,000 | 735,000 | ||
| 2023-05-19 | Calais Philippe Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 |
Page 1 of 2 · 37 trades